Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 13/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.46 |
| ▸ | TGFBR2 | P37173 | 7/20 | 0.45 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | TGFB2 | P61812 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31493019 | 0.83 | TGFBR1 (0.46) | TGFBR1JAK2JAK1TYK2MAPKAPK2 | |
| SCHEMBL30755574 | 0.81 | TYK2 (0.40) | TGFBR1JAK2JAK1TYK2SYK | |
| SCHEMBL30755565 | 0.80 | JAK1 (0.39) | TGFBR1JAK1TYK2SYK | |
| SCHEMBL30755879 | 0.79 | ADORA3 (0.40) | TGFBR1JAK2JAK1TYK2MAPKAPK2 | |
| SCHEMBL30756262 | 0.79 | TYK2 (0.48) | TGFBR1JAK2JAK1TYK2SYK | |
| SCHEMBL32667289 | 0.78 | MAP4K1 (0.45) | JAK2JAK1TYK2SYK | |
| SCHEMBL32667156 | 0.78 | MAP4K1 (0.45) | JAK2JAK1TYK2SYK | |
| SCHEMBL30755764 | 0.77 | PDE4A (0.39) | TGFBR1JAK2JAK1TYK2TGFBR2 | |
| SCHEMBL30755580 | 0.77 | MAP4K1 (0.39) | JAK2JAK1TYK2SYK | |
| SCHEMBL30756327 | 0.77 | TYK2 (0.43) | TGFBR1JAK2JAK1TYK2TGFBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC (US) | 2026-01-29 | — | — | US | disclosed |
| CN-119894879-A | Tyrosine kinase 2 inhibitors and uses thereof | 渤健马萨诸塞州股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | TYK2, ERBB2, ROS1 | TGFBR1 388/4885JAK2 4/4885JAK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.